<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402285</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000505501</org_study_id>
    <secondary_id>UCSF-03553</secondary_id>
    <secondary_id>UCSF-H5664-22834-04A</secondary_id>
    <nct_id>NCT00402285</nct_id>
  </id_info>
  <brief_title>Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer</brief_title>
  <official_title>The Molecular Effects of Nutrition Supplements (MENS) Prostate Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: The use of lycopene, a substance found in tomatoes, or omega-3 fatty acid&#xD;
      nutritional supplements may keep cancer from growing in patients with prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying lycopene to see how well it works&#xD;
      compared to omega-3 fatty acids or a placebo in treating patients with stage I or stage II&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare gene expression in normal prostate tissue (at baseline and after treatment) of&#xD;
           patients with stage I or II adenocarcinoma of the prostate treated with lycopene vs&#xD;
           omega-3 fatty acid nutritional supplements vs placebo.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine new candidate molecular targets for lycopene and omega-3 response pathways.&#xD;
&#xD;
        -  Correlate baseline gene expression patterns, determined by cDNA array analysis, with&#xD;
           self-reported dietary intake.&#xD;
&#xD;
        -  Correlate gene expression patterns with progression or lack of progression at 12 months&#xD;
           after study entry.&#xD;
&#xD;
        -  Determine if lycopene or omega-3 supplements affect the incidence of tumor progression.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled study. Patients are stratified according to&#xD;
      dietary intake of tomato and fish (low tomato [&lt; 4 servings/week], low fish [&lt; 2&#xD;
      servings/week] vs low tomato, high fish [≥ 2 servings/week] vs high tomato [≥ 4&#xD;
      servings/week], low fish vs high tomato, high fish). Patients are randomized to 1 of 3&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients maintain normal diet and receive oral omega-3 fatty acids placebo 3&#xD;
           times daily and lycopene placebo twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral lycopene twice daily and oral omega-3 fatty acids placebo&#xD;
           3 times daily.&#xD;
&#xD;
        -  Arm III: Patients receive oral lycopene placebo twice daily and oral omega-3 fatty acids&#xD;
           3 times daily.&#xD;
&#xD;
      In all arms, treatment continues for up to 90 days or until post-treatment biopsy is&#xD;
      scheduled (a maximum of 104 days) in the absence of disease progression.&#xD;
&#xD;
      Patients complete a dietary questionnaire at baseline and then for 3 days each month during&#xD;
      study therapy. Quality of life is assessed at baseline and at 3 months.&#xD;
&#xD;
      Prostate tissue needle biopsies and blood samples are collected at baseline and at 3 months.&#xD;
      Tissue and blood samples are examined for lycopene and omega-3 fatty acids (treatment&#xD;
      compliance), omega-6 fatty acids, insulin-like growth factor (IGF)-1, IGF binding protein-5,&#xD;
      and cyclooxygenase-2 gene by polymerase chain reaction, cDNA microarray hybridization, and&#xD;
      other gene expression assays.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 114 patients will be enrolled in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Normal Prostate Tissue Gene Expression Between the Baseline and 3-month Biopsies in IGF -1 and COX -2</measure>
    <time_frame>baseline through 3 month</time_frame>
    <description>Comparisons of the change in deltaCT were between the placebo and Lycopene arms for IGF-1 and IGF-1R and between the placebo and fish oil arms for COX-2. Data in the table are mean changes in qRTPCR gene expression (normalized to GUSb) for IGF1, Cox2, and IGF1R.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>lycopene supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two 15mg lycopene capsules daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fish oil supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1g fish oil capsule daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebos for lycopene and fish oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lycopene supplement</intervention_name>
    <arm_group_label>lycopene supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fish oil supplement</intervention_name>
    <arm_group_label>fish oil supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebos for lycopene and fish oil.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Small cell acinar type&#xD;
&#xD;
               -  Gleason score ≤ 6 with no pattern 4 or 5 histology&#xD;
&#xD;
                    -  Gleason pattern 4 seen as a microfocus (&lt; 2 mm in length) allowed&#xD;
&#xD;
               -  Stage I-II (T1 or T2a) disease&#xD;
&#xD;
          -  Must have had an extended pattern biopsy (defined as 8+ cores) within the past 2 years&#xD;
&#xD;
               -  Patients meeting all of the eligibility criteria except for the aforementioned&#xD;
                  extended pattern biopsy within the past two years may enroll in the study if they&#xD;
                  have an extended pattern clinical biopsy scheduled no more than 6 weeks before&#xD;
                  beginning study treatment AND are willing to have an additional 4 biopsy cores&#xD;
&#xD;
          -  No more than 33% of biopsy cores positive&#xD;
&#xD;
               -  33% or more of biopsy cores positive due to microfoci of adenocarcinoma allowed&#xD;
&#xD;
          -  No more than 50% of the length of a tumor core involved by carcinoma&#xD;
&#xD;
          -  Watchful waiting planned as primary treatment strategy&#xD;
&#xD;
          -  Must have 3 serum prostate-specific antigen (PSA) level readings taken ≥ 2 weeks apart&#xD;
             over the past year&#xD;
&#xD;
               -  PSA ≤ 10.0 ng/mL&#xD;
&#xD;
                    -  PSA &lt; 15 ng/mL in patients with benign prostatic hyperplasia or prostatitis&#xD;
                       allowed&#xD;
&#xD;
               -  PSA doubling time ≥ 3 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  No history of allergic reactions attributed to tomatoes, fish, soybean oil, gelatin&#xD;
             capsules, or compounds of similar chemical or biologic composition to lycopene&#xD;
             (carotenoids) or fish oil (omega-3 fatty acids)&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior or concurrent treatment for prostate cancer, including surgery, radiation,&#xD;
             hormonal therapy (e.g., leuprolide acetate, bicalutamide, flutamide, goserelin,&#xD;
             megestrol, nilutamide, diethylstilbestrol/estrogen), chemotherapy, PC-SPES, or&#xD;
             investigational agents&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent lycopene, fish oil (omega-3 fatty&#xD;
             acids), or any other preparation intended to supplement levels of omega-3 unsaturated&#xD;
             fatty acids&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent finasteride, dutasteride, saw palmetto&#xD;
             or any other herbal/nutritional preparation indicated to affect hormone levels&#xD;
&#xD;
          -  More than 1 month since prior nonsteroidal anti-inflammatory drugs (NSAIDs),&#xD;
             cyclooxygenase-2 (COX-2) inhibitors, and/or aspirin for &gt; 7 days duration&#xD;
&#xD;
          -  No concurrent NSAIDs, COX-2 inhibitors, or aspirin&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter R. Carroll, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS One. 2011;6(9):e24004. doi: 10.1371/journal.pone.0024004. Epub 2011 Sep 1.</citation>
    <PMID>21912659</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>September 13, 2012</results_first_submitted>
  <results_first_submitted_qc>April 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potentially eligible men identified at Urologic Oncology clinic at Helen Diller Family Comprehensive Cancer Center San Francisco starting in 2003.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lycopene Supplement</title>
          <description>two 15mg lycopene soft gel capsules daily (Lyc-O-Mato). men took lycopene &amp; placebo for fish oil.</description>
        </group>
        <group group_id="P2">
          <title>Fish Oil Supplement</title>
          <description>three 1g fish oil capsules daily including 1,098mg EPA &amp; 549mg DHA fatty acid (Roche).&#xD;
men took fish oil &amp; placebo for lycopene.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>men took placebo for lycopene &amp; placebo for fish oil.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>insufficient RNA quality</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lycopene Supplement</title>
          <description>two 15mg lycopene soft gel capsules daily (Lyc-O-Mato). men took lycopene &amp; placebo for fish oil.</description>
        </group>
        <group group_id="B2">
          <title>Fish Oil Supplement</title>
          <description>three 1g fish oil capsules daily including 1,098mg EPA &amp; 549mg DHA fatty acid (Roche).&#xD;
men took fish oil &amp; placebo for lycopene.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>men took placebo for lycopene &amp; placebo for fish oil.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="7"/>
                    <measurement group_id="B2" value="62" spread="8"/>
                    <measurement group_id="B3" value="59" spread="8"/>
                    <measurement group_id="B4" value="61" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Normal Prostate Tissue Gene Expression Between the Baseline and 3-month Biopsies in IGF -1 and COX -2</title>
        <description>Comparisons of the change in deltaCT were between the placebo and Lycopene arms for IGF-1 and IGF-1R and between the placebo and fish oil arms for COX-2. Data in the table are mean changes in qRTPCR gene expression (normalized to GUSb) for IGF1, Cox2, and IGF1R.</description>
        <time_frame>baseline through 3 month</time_frame>
        <population>1 ppt randomized to fish oil had un-evaluable COX-2 at 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Lycopene Supplement</title>
            <description>two 15mg lycopene soft gel capsules daily (Lyc-O-Mato). men took lycopene &amp; placebo for fish oil.</description>
          </group>
          <group group_id="O2">
            <title>Fish Oil Supplement</title>
            <description>three 1g fish oil capsules daily including 1,098mg EPA &amp; 549mg DHA fatty acid (Roche).&#xD;
men took fish oil &amp; placebo for lycopene.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>men took placebo for lycopene &amp; placebo for fish oil.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Normal Prostate Tissue Gene Expression Between the Baseline and 3-month Biopsies in IGF -1 and COX -2</title>
          <description>Comparisons of the change in deltaCT were between the placebo and Lycopene arms for IGF-1 and IGF-1R and between the placebo and fish oil arms for COX-2. Data in the table are mean changes in qRTPCR gene expression (normalized to GUSb) for IGF1, Cox2, and IGF1R.</description>
          <population>1 ppt randomized to fish oil had un-evaluable COX-2 at 3 months.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.32"/>
                    <measurement group_id="O2" value="NA" spread="NA">we did not measure IGF for fish oil</measurement>
                    <measurement group_id="O3" value="0.02" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COX-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">we did not measure COX-2 for lycopene</measurement>
                    <measurement group_id="O2" value="0.39" spread="1.98"/>
                    <measurement group_id="O3" value="0.40" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-1R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="3.00"/>
                    <measurement group_id="O2" value="NA" spread="NA">we did not measure IGF for fish oil</measurement>
                    <measurement group_id="O3" value="0.74" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Carroll, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-353-7098</phone>
      <email>pcarroll@urology.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

